Polyethylene glycol immunogenicity in nanomedicine
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Their stability in biological environments is improved through coatings, such as polyethylene glycol (PEG), dextran, or silica, which prevent aggregation and improve dispersion. These coatings further help in reducing immunogenic responses [59].”
From Advances in green-synthesized magnetic nanoparticles for targeted cancer therapy: mechanisms, applications, and future perspectives (2026) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Of Mice and Not Men: Differences between Mouse and Human Immunology
Mestas, J., & Hughes, C. C. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2731 · Cited by 3,822
Cheng, Q., Wei, T., Farbiak, L., Johnson, L. T., Dilliard, S. A., & Siegwart, D. J. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0669-6 · Cited by 2,383
Nanoparticle Size and Surface Chemistry Determine Serum Protein Adsorption and Macrophage Uptake
Walkey, C. D., Olsen, J. B., Guo, H., Emili, A., & Chan, W. C. W. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2084338 · Cited by 1,926
Targeting drugs to tumours using cell membrane-coated nanoparticles
Fang, R. H., Gao, W., & Zhang, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00699-x · Cited by 980
Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy
Yong, T., Zhang, X., Bie, N., Zhang, H., Zhang, X., Li, F., Hakeem, A., Hu, J., Gan, L., Santos, H. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11718-4 · Cited by 806
Kozma, G. T., Shimizu, T., Ishida, T., & Szebeni, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.024 · Cited by 696
Hoang Thi, T. T., Pilkington, E. H., Nguyen, D. H., Lee, J. S., Park, K. D., & Truong, N. P. (2020) · Polymers · doi:10.3390/polym12020298 · Cited by 668
New concepts in the generation and functions of IgA
Pabst, O. (2012) · Nature reviews. Immunology · doi:10.1038/nri3322 · Cited by 656
Research works printed but not linked: 222
- Davis, F. F. The origin of pegnology. Adv. Drug Deliv. Rev. 54, 457–458 (2002). · DOI · Paper page
- Gao, Y., Joshi, M., Zhao, Z. & Mitragotri, S. PEGylated therapeutics in the clinic. Bioeng. Transl. Med. 9, e10600 (2024). · DOI · Paper page
- Arturson, P., Laakso, T. & Edman, P. Acrylic microspheres in vivo IX: blood elimination kinetics and organ distribution of microparticles with different surface characteristics. J. Pharm. Sci. 72, 1415–1420 (1983). · DOI
- Klibanov, A. L., Maruyama, K., Torchilin, V. P. & Huang, L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268, 235–237 (1990). · DOI · Paper page
- López-Estevez, A. M., Gref, R. & Alonso, M. J. A journey through the history of PEGylated drug delivery nanocarriers. Drug Deliv. Transl. Res. 14, 1–6 (2024). · DOI
- Du, X. J. et al. Regulating the surface poly(ethylene glycol) density of polymeric nanoparticles and evaluating its role in drug delivery in vivo. Biomaterials 69, 1–11 (2015). · DOI
- Chen, B.-M. et al. Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals. Anal. Chem. 88, 10661–10666 (2016). This article reports detailed assay validation and measurement of pre-existing anti-PEG antibodies in a large cohort of healthy donors. · DOI · Paper page
- Yang, Q. et al. Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population. Anal. Chem. 88, 11804–11812 (2016). · DOI · Paper page
- Ju, Y. et al. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine. ACS Nano 16, 11769–11780 (2022). This article reports that COVID 19 mRNA vaccines can increase the concentrations of both anti-PEG IgG and IgM antibodies. · DOI · Paper page
- Chen, B. M., Cheng, T. L. & Roffler, S. R. Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies. ACS Nano 15, 14022–14048 (2021). This review discusses PEG immunogenicity and anti-PEG antibodies. · DOI · Paper page
- Bavli, Y. et al. Anti-PEG antibodies before and after a first dose of Comirnaty® (mRNA-LNP-based SARS-CoV-2 vaccine). J. Control. Rel. 354, 316–322 (2023). · DOI
- Tenchov, R., Sasso, J. M. & Zhou, Q. A. PEGylated lipid nanoparticle formulations: immunological safety and efficiency perspective. Bioconjug. Chem. 34, 941–960 (2023). · DOI · Paper page
- Fu, J., Wu, E., Li, G., Wang, B. & Zhan, C. Anti-PEG antibodies: current situation and countermeasures. Nano Today 55, 102163 (2024). · DOI
- Gaballa, S. A. et al. Treatment-induced and pre-existing anti-PEG antibodies: prevalence, clinical implications, and future perspectives. J. Pharm. Sci. 113, 555–578 (2024). · DOI
- Simberg, D. & Moghimi, S. M. Anti-poly (ethylene glycol)(PEG) antibodies: from where are we coming and where are we going. J. Nanotheranos. 5, 99–103 (2024). · DOI
- Lee, C.-C. et al. Structural basis of polyethylene glycol recognition by antibody. J. Biomed. Sci. 27, 1–13 (2020). · DOI · Paper page
- Huckaby, J. T. et al. Structure of an anti-PEG antibody reveals an open ring that captures highly flexible PEG polymers. Commun. Chem. 3, 124 (2020). · DOI
- Nguyen, M.-T. T. et al. Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group. Commun. Chem. 5, 88 (2022). · DOI
- Su, Y. C. et al. Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy. Nat. Commun. 8, 15507 (2017). This article reports that pre-targeting bispecific PEG engagers to cancer cells can enhance internalization and efficacy of PEGylated nanomedicines. · DOI · Paper page
- Chang, T.-C., Chen, B.-M., Wu, J.-Y., Cheng, T.-L. & Roffler, S. Impact of anti-PEG antibody affinity on accelerated blood clearance of pegylated epoetin beta in mice. Biomed. Pharmacother. 146, 112502 (2022). · DOI
- Hsiao, C. Y. et al. Engineering a high-affinity anti-methoxy poly(ethylene glycol) (mPEG) antibody for sensitive immunosensing of mPEGylated therapeutics and mPEG molecules. Bioconjug. Chem. 33, 2180–2188 (2022). · DOI
- Su, Y. C., Chen, B. M., Chuang, K. H., Cheng, T. L. & Roffler, S. R. Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies. Bioconjug. Chem. 21, 1264–1270 (2010). · DOI · Paper page
- Mima, Y., Hashimoto, Y., Shimizu, T., Kiwada, H. & Ishida, T. Anti-PEG IgM is a major contributor to the accelerated blood clearance of polyethylene glycol-conjugated protein. Mol. Pharm. 12, 2429–2435 (2015). · DOI · Paper page
- Kozma, G. T. et al. Pseudo-anaphylaxis to polyethylene glycol (PEG)-coated liposomes: roles of anti-PEG IgM and complement activation in a porcine model of human infusion reactions. ACS Nano 13, 9315–9324 (2019). · DOI · Paper page
- Moghimi, S. M. et al. Perspectives on complement and phagocytic cell responses to nanoparticles: from fundamentals to adverse reactions. J. Control. Rel. 356, 115–129 (2023). · DOI
- Liu, Y. et al. The strategy used by naïve anti-PEG antibodies to capture flexible and featureless PEG chains. J. Control. Rel. 380, 396–403 (2025). · doi:10.1016/j.jconrel.2025.02.001
- Povsic, T. J. et al. Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. J. Allergy Clin. Immunol. 138, 1712–1715 (2016). · DOI · Paper page
- Sellaturay, P., Nasser, S., Islam, S., Gurugama, P. & Ewan, P. W. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID‐19 vaccine. Clin. Exp. Allergy 51, 861 (2021). · DOI · Paper page
- Chen, B.-M. et al. Liposomes with low levels of grafted poly(ethylene glycol) remain susceptible to destabilization by anti-poly(ethylene glycol) antibodies. ACS Nano 18, 22122–22138 (2024). · DOI
- Chen, E. et al. Premature drug release from polyethylene glycol (PEG)-coated liposomal doxorubicin via formation of the membrane attack complex. ACS Nano 14, 7808–7822 (2020). · DOI · Paper page
- Li, Y. et al. Complement opsonization of nanoparticles: differences between humans and preclinical species. J. Control. Rel. 338, 548–556 (2021). · DOI
- Chen, W.-A. et al. Antibodies against poly (ethylene glycol) activate innate immune cells and induce hypersensitivity reactions to PEGylated nanomedicines. ACS Nano 17, 5757–5772 (2023). This article reports the mechanism of hypersensitivity reactions induced by anti-PEG IgG antibodies against nanomedicines. · DOI
- Warren, C. M. et al. Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system. JAMA Netw. Open 4, e2125524 (2021). · DOI · Paper page
- Troelnikov, A. et al. Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy. J. Allergy Clin. Immunol. 148, 91–95 (2021). · DOI
- Mouri, M. et al. Serum polyethylene glycol-specific IgE and IgG in patients with hypersensitivity to COVID-19 mRNA vaccines. Allergol. Int. 71, 512–519 (2022). · DOI
- Kan, A. K. C., Chiang, V., Ip, W. K., Au, E. Y. & Li, P. H. Anti‐polyethylene glycol (PEG) antibody isotypes may predict PEG‐associated allergy and COVID‐19 protection among patients with history of suspected COVID‐19 vaccine allergy. Clin. Transl. Allergy 13, e12284 (2023). · doi:10.1002/clt2.12284
- Prussin, C. & Metcalfe, D. D. IgE, mast cells, basophils, and eosinophils. J. Allergy Clin. Immunol. 111, S486–S494 (2003). · DOI · Paper page
- Zhou, Z.-H. et al. Anti-PEG IgE in anaphylaxis associated with polyethylene glycol. J. Allergy Clin. Immunol. Pract. 9, 1731–1733.e3 (2021). · DOI · Paper page
- Lubich, C. et al. The mystery of antibodies against polyethylene glycol (PEG) — what do we know? Pharm. Res. 33, 2239–2249 (2016). · DOI · Paper page
- Deuker, M. F., Mailänder, V., Morsbach, S. & Landfester, K. Anti-PEG antibodies enriched in the protein corona of PEGylated nanocarriers impact the cell uptake. Nanoscale Horiz. 8, 1377–1385 (2023). · DOI
- Ibrahim, M. et al. Investigation of anti-PEG antibody response to PEG-containing cosmetic products in mice. J. Control. Rel. 354, 260–267 (2023). · DOI
- Chang, C.-J. et al. A genome-wide association study identifies a novel susceptibility locus for the immunogenicity of polyethylene glycol. Nat. Commun. 8, 522 (2017). · DOI · Paper page
- Shen, L. et al. Free PEG suppresses anaphylaxis to PEGylated nanomedicine in swine. ACS Nano 18, 8733–8744 (2024). This article reports that free PEG can help block hypersensitivity reactions caused by anti-PEG antibodies in a large animal model. · DOI
- Stavnsbjerg, C. et al. Accelerated blood clearance and hypersensitivity by PEGylated liposomes containing TLR agonists. J. Control. Rel. 342, 337–344 (2022). · DOI
- Guerrini, G. et al. Monitoring anti-PEG antibodies level upon repeated lipid nanoparticle-based COVID-19 vaccine administration. Int. J. Mol. Sci. 23, 8838 (2022). · DOI · Paper page
- Kozma, G. T. et al. Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing COVID-19 vaccines: evidence for immunogenicity of PEG. Vaccine 41, 4561–4570 (2023). · DOI · Paper page
- Li, Y. et al. Optimized enzyme-linked immunosorbent assay for anti-PEG antibody detection in healthy donors and patients treated with PEGylated liposomal doxorubicin. Mol. Pharm. 21, 3053–3060 (2024). · DOI
- Moghimi, S. M. The effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG liposomes. Biomaterials 27, 136–144 (2006). · DOI
- Reddy, S. T. et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 25, 1159–1164 (2007). · DOI · Paper page
- Nakamura, T. et al. The effect of size and charge of lipid nanoparticles prepared by microfluidic mixing on their lymph node transitivity and distribution. Mol. Pharm. 17, 944–953 (2020). · DOI · Paper page
- Lee, Y. et al. Development of lipid nanoparticle formulation for the repeated administration of mRNA therapeutics. Biomater. Res. 28, 0017 (2024). · DOI
- Kavita, U., Miller, W., Ji, Q. C. & Pillutla, R. C. A fit-for-purpose method for the detection of human antibodies to surface-exposed components of BMS-986263, a lipid nanoparticle-based drug product containing a siRNA drug substance. AAPS J. 21, 1–13 (2019). · DOI
- Lin, Y. C. et al. Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture. J. Control. Rel. 354, 354–367 (2023). · DOI
- Li, Z. et al. Development of anti-PEG IgG/IgM/IgE ELISA assays for profiling anti-PEG immunoglobulin response in PEG-sensitized individuals and patients with alpha-gal allergy. J. Control. Rel. 366, 342–348 (2024). · DOI
- Pengo, V., Biasiolo, A., Bison, E., Chantarangkul, V. & Tripodi, A. Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-β2-glycoprotein I activity. Thromb. Res. 120, 127–133 (2007). · DOI
- Moghimi, S. M., Simberg, D., Skotland, T., Yaghmur, A. & Hunter, A. C. The interplay between blood proteins, complement, and macrophages on nanomedicine performance and responses. J. Pharmacol. Exp. Ther. 370, 581–592 (2019). · DOI · Paper page
- Moghimi, S. M., Simberg, D., Papini, E. & Farhangrazi, Z. S. Complement activation by drug carriers and particulate pharmaceuticals: principles, challenges and opportunities. Adv. Drug Deliv. Rev. 157, 83–95 (2020). · DOI
- Vu, V. P. et al. Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles. Nat. Nanotechnol. 14, 260–268 (2019). · DOI · Paper page
- Li, Y. et al. Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins. Nat. Nanotechnol. 19, 246–254 (2024). This article reports the design of recombinant complement inhibitors to improve nanomedicine efficacy and safety. · DOI
- Li, Y. et al. Nanoparticle-binding immunoglobulins predict variable complement responses in healthy and diseased cohorts. ACS Nano 18, 28649–28658 (2024). · DOI
- Mak, T. W. & Saunders, M. E. The Immune Response: Basic and Clinical Principles (Academic Press, 2005).
- Pedersen, M. B. et al. Curvature of synthetic and natural surfaces is an important target feature in classical pathway complement activation. J. Immunol. 184, 1931–1945 (2010). · DOI · Paper page
- Feinstein, A., Richardson, N. & Taussig, M. I. Immunoglobulin flexibility in complement activation. Immunol. Today 7, 169–174 (1986). · DOI
- Lachmann, P. J. Looking back on the alternative complement pathway. Immunobiology 223, 519–523 (2018). · DOI
- Nagayama, S., Ogawara, K.-I, Fukuoka, Y., Higaki, K. & Kimura, T. Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. Int. J. Pharm. 342, 215–221 (2007). · DOI · Paper page
- Aragnol, D. & Leserman, L. D. Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. Proc. Natl Acad. Sci. USA 83, 2699–2703 (1986). · DOI · Paper page
- Ishida, T. et al. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J. Control. Rel. 112, 15–25 (2006). · DOI · Paper page
- Ishida, T. & Kiwada, H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int. J. Pharm. 354, 56–62 (2008). · DOI · Paper page
- Lin, S. et al. Reexamining in vivo fate of paclitaxel-loaded polymeric micelles. Nano Today 56, 102255 (2024). · DOI
- Hsieh, Y. C. et al. Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes. Theranostics 8, 3164–3175 (2018). · DOI · Paper page
- Chang, T. C. et al. Both IgM and IgG antibodies against polyethylene glycol can alter the biological activity of methoxy polyethylene glycol-epoetin beta in mice. Pharmaceutics 12, 15 (2019). · DOI
- Omata, D. et al. Effect of anti-PEG antibody on immune response of mRNA-loaded lipid nanoparticles. Mol. Pharm. 21, 5672–5680 (2024). · DOI
- Yang, M. et al. Effects of PEG antibodies on in vivo performance of LNP-mRNA vaccines. Int. J. Pharm. 650, 123695 (2024). · DOI
- Liu, Y.-L. et al. Impact of pre-existing anti-polyethylene glycol antibodies on the pharmacokinetics and efficacy of a COVID-19 mRNA vaccine (Comirnaty) in vivo. Biomater. Res. 28, 0112 (2024). · DOI
- Senti, M. E. et al. Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement. J. Control. Rel. 341, 475–486 (2022). · DOI · Paper page
- Semple, S. C. et al. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol–lipid conjugates and nucleic acid. J. Pharmacol. Exp. Ther. 312, 1020–1026 (2005). · DOI · Paper page
- Judge, A., McClintock, K., Phelps, J. R. & MacLachlan, I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol. Ther. 13, 328–337 (2006). · DOI · Paper page
- Kikuchi, Y. & Kaplan, A. P. A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. J. Allergy Clin. Immunol. 109, 114–118 (2002). · DOI · Paper page
- El-Lati, S. G., Church, M. K. & Dahinden, C. A. Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells. J. Invest. Dermatol. 102, 803–806 (1994). · DOI · Paper page
- Guo, R.-F. & Ward, P. A. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23, 821–852 (2005). · DOI · Paper page
- Jönsson, F. et al. An IgG-induced neutrophil activation pathway contributes to human drug-induced anaphylaxis. Sci. Transl. Med. 11, eaat1479 (2019). · DOI · Paper page
- Vultaggio, A. et al. Manifestations of antidrug antibodies response: hypersensitivity and infusion reactions. J. Interferon Cytokine Res. 34, 946–952 (2014). · DOI
- Weber, F. et al. First infusion reactions are mediated by FcγRIIIb and neutrophils. Pharm. Res. 35, 1–11 (2018). · DOI
- Jönsson, F. et al. Mouse and human neutrophils induce anaphylaxis. J. Clin. Invest. 121, 1484–1496 (2011). · DOI · Paper page
- Moghimi, S. M. & Simberg, D. Translational gaps in animal models of human infusion reactions to nanomedicines. Nanomedicine 13, 973–975 (2018). · doi:10.2217/nnm-2018-0064
- Ong, G. L. & Mattes, M. J. Mouse strains with typical mammalian levels of complement activity. J. Immunol. Methods 125, 147–158 (1989). · DOI
- Beutier, H. et al. Platelets expressing IgG receptor FcγRIIA/CD32A determine the severity of experimental anaphylaxis. Sci. Immunol. 3, eaan5997 (2018). · DOI
- Li, S. et al. Voluntary‐opsonization‐enabled precision nanomedicines for inflammation treatment. Adv. Mater. 33, 2006160 (2021). · DOI
- Armstrong, R. A. Alzheimer’s disease and the eye. J. Optom. 2, 103–111 (2009). · DOI · Paper page
- Lipsky, P. E. et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res. Ther. 16, 1–8 (2014). · DOI · Paper page
- Gupta, S. et al. Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials. eBioMedicine 37, 366–373 (2018). · DOI
- Takata, H. et al. Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route. J. Control. Rel. 360, 285–292 (2023). This article demonstrates the effect of administration routes on the production of anti-PEG antibodies induced by PEGylated liposomes. · DOI
- Grenier, P., Chenard, V. & Bertrand, N. The mechanisms of anti-PEG immune response are different in the spleen and the lymph nodes. J. Control. Rel. 353, 611–620 (2023). · DOI
- Münter, R., Christensen, E., Andresen, T. L. & Larsen, J. B. Studying how administration route and dose regulates antibody generation against LNPs for mRNA delivery with single-particle resolution. Mol. Ther. Methods Clin. Dev. 29, 450–459 (2023). · DOI
- Kagan, L. et al. The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. Eur. J. Pharm. Biopharm. 67, 759–765 (2007). · DOI
- Wang, H. et al. Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles in rats. npj Vaccines 8, 169 (2023). · DOI
- Kent, S. J. et al. Blood distribution of SARS-CoV-2 lipid nanoparticle mRNA vaccine in humans. ACS Nano 18, 27077–27089 (2024). · DOI
- McSweeney, M. D. et al. Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG. J. Control. Rel. 311, 138–146 (2019). · DOI
- McSweeney, M. D. et al. Pre-treatment with high molecular weight free PEG effectively suppresses anti-PEG antibody induction by PEG-liposomes in mice. J. Control. Rel. 329, 774–781 (2021). · DOI
- Fletcher, A. M. et al. Adverse vacuolation in multiple tissues in cynomolgus monkeys following repeat-dose administration of a PEGylated protein. Toxicol. Lett. 317, 120–129 (2019). · DOI
- Chiang, V. et al. Polyethylene glycol allergy: risks of skin testing and complement-mediated anaphylaxis. J. Investig. Allergol. Clin. Immunol. 71–73 (2023). · doi:10.18176/jiaci.0813
- Hamad, I., Hunter, A., Szebeni, J. & Moghimi, S. M. Poly (ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol. Immunol. 46, 225–232 (2008). · DOI · Paper page
- Liu, M. et al. Branched PEG-modification: a new strategy for nanocarriers to evade of the accelerated blood clearance phenomenon and enhance anti-tumor efficacy. Biomaterials 283, 121415 (2022). · DOI
- Liu, M. et al. ‘Y-type’ PEG modified liposomes could eliminate the accelerated blood clearance (ABC) phenomenon and improved tumor therapy. Appl. Mater. Today 32, 101853 (2023). · DOI
- Maiti, D., Yokoyama, M. & Shiraishi, K. Impact of the hydrophilicity of poly (sarcosine) on poly (ethylene glycol)(PEG) for the suppression of anti-PEG antibody binding. ACS Omega 9, 34577–34588 (2024). · DOI
- Xu, H., Wang, K. Q., Deng, Y. H. & Chen, D. W. Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes. Biomaterials 31, 4757–4763 (2010). · DOI
- Suzuki, T. et al. PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: faster PEG shedding attenuates anti-PEG IgM production. Int. J. Pharm. 588, 119792 (2020). · DOI · Paper page
- Sui, D. et al. Cleavable-branched polymer-modified liposomes reduce accelerated blood clearance and enhance photothermal therapy. ACS Appl. Mater. Interfaces 15, 32110–32120 (2023). · DOI
- Pannuzzo, M. et al. Overcoming nanoparticle-mediated complement activation by surface PEG pairing. Nano Lett. 20, 4312–4321 (2020). · DOI · Paper page
- Tian, Y. et al. Engineering poly (ethylene glycol) nanoparticles for accelerated blood clearance inhibition and targeted drug delivery. J. Am. Chem. Soc. 144, 18419–18428 (2022). · DOI
- Meszaros, T. et al. Factor H inhibits complement activation induced by liposomal and micellar drugs and the therapeutic antibody rituximab in vitro. Nanomedicine 12, 1023–1031 (2016). · DOI
- Wang, Z. et al. Combating complement’s deleterious effects on nanomedicine by conjugating complement regulatory proteins to nanoparticles. Adv. Mater. 34, 2107070 (2022). · DOI
- Park, J. H. et al. Cloaking silica nanoparticles with functional protein coatings for reduced complement activation and cellular uptake. ACS Nano 14, 11950–11961 (2020). · DOI · Paper page
- Duong, B. H. et al. Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo. J. Exp. Med. 207, 173 (2010). · DOI · Paper page
- Macauley, M. S. et al. Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis. J. Clin. Invest. 123, 3074–3083 (2013). · DOI · Paper page
- Qian, H. et al. Recent advances on next generation of polyzwitterion-based nano-vectors for targeted drug delivery. J. Control. Rel. 343, 492–505 (2022). · DOI
- Overby, C., Park, S., Summers, A. & Benoit, D. S. W. Zwitterionic peptides: tunable next-generation stealth nanoparticle modifications. Bioact. Mater. 27, 113–124 (2023).
- Banskota, S. et al. Genetically encoded stealth nanoparticles of a zwitterionic polypeptide–paclitaxel conjugate have a wider therapeutic window than Abraxane in multiple tumor models. Nano Lett. 20, 2396–2409 (2020). · DOI
- Jackson, M. A. et al. Zwitterionic nanocarrier surface chemistry improves siRNA tumor delivery and silencing activity relative to polyethylene glycol. ACS Nano 11, 5680–5696 (2017). This article demonstrates the potential of zwitterionic polymers as PEG alternatives for the creation of stealth nanomedicines. · DOI
- Lee, J. et al. Ultrastable and redispersible zwitterionic bottlebrush micelles for drug delivery. ACS Appl. Mater. Interfaces 16, 55118–55129 (2024).
- Moitra, P. et al. Context-responsive nanoparticle derived from synthetic zwitterionic ionizable phospholipids in targeted CRISPR/Cas9 therapy for basal-like breast cancer. ACS Nano 18, 9199–9220 (2024). · DOI
- Zhang, Z., Sun, H., Giannino, J., Wu, Y. & Cheng, C. Biodegradable zwitterionic polymers as PEG alternatives for drug delivery. J. Polym. Sci. 62, 2231–2250 (2024). · DOI
- Najmina, M. et al. A stealthiness evaluation of main chain carboxybetaine polymer modified into liposome. Pharmaceutics 16, 1271 (2024). · DOI
- Sanchez, A. et al. Substituting poly(ethylene glycol) lipids with poly(2-ethyl-2-oxazoline) lipids improves lipid nanoparticle repeat dosing. Adv. Healthc. Mater. 13, e2304033 (2024). · DOI
- Rajesh, S. et al. Lipidic poly (2-oxazoline)s as PEG replacement steric stabilisers for cubosomes. J. Colloid Sci. 623, 1142–1150 (2022). · DOI
- Tavano, R. et al. C1q-mediated complement activation and C3 opsonization trigger recognition of stealth poly (2-methyl-2-oxazoline)-coated silica nanoparticles by human phagocytes. ACS Nano 12, 5834–5847 (2018). · DOI · Paper page
- Hoogenboom, R. & Schlaad, H. Thermoresponsive poly (2-oxazoline)s, polypeptoids, and polypeptides. Polym. Chem. 8, 24–40 (2017). · DOI · Paper page
- Kang, D. D. et al. Engineering LNPs with polysarcosine lipids for mRNA delivery. Bioact. Mater. 37, 86–93 (2024).
- Bayraktutan, H. et al. Polysarcosine functionalised cationic polyesters efficiently deliver self-amplifying mRNA. Polym. Chem. 15, 1862–1876 (2024). · DOI
- Yao, X., Qi, C., Sun, C., Huo, F. & Jiang, X. Poly (ethylene glycol) alternatives in biomedical applications. Nano Today 48, 101738 (2023). · DOI
- Hara, E. et al. Pharmacokinetic change of nanoparticulate formulation ‘Lactosome’ on multiple administrations. Int. Immunopharmacol. 14, 261–266 (2012). · DOI
- Negwer, I. et al. Monitoring drug nanocarriers in human blood by near-infrared fluorescence correlation spectroscopy. Nat. Commun. 9, 5306 (2018). · DOI · Paper page
- Berger, M. et al. Poly (vinyl pyrrolidone) derivatives as PEG alternatives for stealth, non-toxic and less immunogenic siRNA-containing lipoplex delivery. J. Control. Rel. 361, 87–101 (2023). · DOI
- Wu, L.-P. et al. Dendrimer end-terminal motif-dependent evasion of human complement and complement activation through IgM hitchhiking. Nat. Commun. 12, 4858 (2021). · DOI
- Janaszewska, A. et al. Pyrrolidone modification prevents PAMAM dendrimers from activation of pro-inflammatory signaling pathways in human monocytes. Mol. Pharm. 15, 12–20 (2018). · DOI
- Axioti, E. et al. Glycerol- and diglycerol-based polyesters: evaluation of backbone alterations upon nano-formulation performance. Colloids Surf. B Biointerfaces 236, 113828 (2024). · DOI
- Soshee, A., Zürcher, S., Spencer, N. D., Halperin, A. & Nizak, C. General in vitro method to analyze the interactions of synthetic polymers with human antibody repertoires. Biomacromolecules 15, 113–121 (2014). · DOI
- Hulugalla, K. et al. Glycopolymeric nanoparticles enrich less immunogenic protein coronas, reduce mononuclear phagocyte clearance, and improve tumor delivery compared to PEGylated nanoparticles. ACS Nano 18, 30540–30560 (2024). · DOI · Paper page
- Hassanel, D. N. B. et al. Replacing poly (ethylene glycol) with RAFT lipopolymers in mRNA lipid nanoparticle systems for effective gene delivery. Int. J. Pharm. 665, 124695 (2024). · DOI
- Perrier, S. 50th anniversary perspective: RAFT polymerization. A user guide. Macromolecules 50, 7433–7447 (2017). · DOI · Paper page
- Safdar, A., Wang, P., Muhaymin, A., Nie, G. & Li, S. From bench to bedside: platelet biomimetic nanoparticles as a promising carriers for personalized drug delivery. J. Control. Rel. 373, 128–144 (2024). · DOI
- Li, S. et al. Protein precoating modulates biomolecular coronas and nanocapsule–immune cell interactions in human blood. J. Mater. Chem. B 10, 7607–7621 (2022). · DOI
- Gravan, P. et al. Exploring the impact of nanoparticle stealth coatings in cancer models: from PEGylation to cell membrane-coating nanotechnology. ACS Appl. Mater. Interfaces 16, 2058–2074 (2024). · DOI
- Hu, C.-M. J. et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature 526, 118–121 (2015). This article demonstrates the potential and advantages of membrane-cloaked nanomedicines. · DOI · Paper page
- Gao, C. et al. Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines. Nat. Commun. 11, 2622 (2020). · DOI · Paper page
- Wang, D. et al. Neuronal membrane-derived nanodiscs for broad-spectrum neurotoxin detoxification. ACS Nano 18, 25069–25080 (2024). · doi:10.1021/acsnano.4c06708
- Zhang, K. et al. Recent advances in cell membrane coated biomimetic nanomedicines: from laboratory research to clinical application. Preprint at Authorea https://doi.org/10.22541/au.171816032.20485120/v1 (2024). · doi:10.22541/au.171816032.20485120/v1
- Chan, M. H. et al. Integrated therapy platform of exosomal system: hybrid inorganic/organic nanoparticles with exosomes for cancer treatment. Nanoscale Horiz. 7, 352–367 (2022). · DOI
- Qin, X. et al. Spontaneously right‐side‐out‐orientated coupling‐driven ROS‐sensitive nanoparticles on cell membrane inner leaflet for efficient renovation in vascular endothelial injury. Adv. Sci. 10, 2205093 (2023). · DOI
- Fan, Z., Zhou, H., Li, P. Y., Speer, J. E. & Cheng, H. Structural elucidation of cell membrane-derived nanoparticles using molecular probes. J. Mater. Chem. B 2, 8231–8238 (2014). · DOI · Paper page
- Iqbal, H. et al. A bioinspired doxorubicin-carried albumin nanocage against aggressive cancer via systemic targeting of tumor and lymph node metastasis. J. Control. Rel. 372, 829–845 (2024). · DOI
- Gheibi Hayat, S. M., Bianconi, V., Pirro, M. & Sahebkar, A. Stealth functionalization of biomaterials and nanoparticles by CD47 mimicry. Int. J. Pharm. 569, 118628 (2019). · DOI
- Jalil, A. R., Tobin, M. P. & Discher, D. E. Suppressing or enhancing macrophage engulfment through the use of CD47 and related peptides. Bioconjug. Chem. 33, 1989–1995 (2022). · DOI
- Gheibi Hayat, S. M., Jaafari, M. R., Hatamipour, M., Jamialahmadi, T. & Sahebkar, A. Harnessing CD47 mimicry to inhibit phagocytic clearance and enhance anti-tumor efficacy of nanoliposomal doxorubicin. Expert Opin. Drug Deliv. 17, 1049–1058 (2020). · doi:10.1080/17425247.2020.1772749
- Spada, A., Emami, J., Tuszynski, J. A. & Lavasanifar, A. The uniqueness of albumin as a carrier in nanodrug delivery. Mol. Pharm. 18, 1862–1894 (2021). · DOI · Paper page
- Zheng, B. et al. Modulating the tumoral SPARC content to enhance albumin-based drug delivery for cancer therapy. J. Control. Rel. 366, 596–610 (2024). · DOI
- Capomaccio, R. et al. Determination of the structure and morphology of gold nanoparticle–HSA protein complexes. Nanoscale 7, 17653–17657 (2015). · DOI
- Zaleski, M. H. et al. Conjugation chemistry markedly impacts toxicity and biodistribution of targeted nanoparticles, mediated by complement activation. Adv. Mater. 37, 2409945 (2024). · DOI
- Blume, J. E. et al. Rapid, deep and precise profiling of the plasma proteome with multi-nanoparticle protein corona. Nat. Commun. 11, 3662 (2020). · DOI · Paper page
- Vaidya, A. et al. Expanding RNAi to kidneys, lungs, and spleen via selective organ targeting (SORT) siRNA lipid nanoparticles. Adv. Mater. 36, 2313791 (2024). This article reports a general approach to target lipid nanoparticles to different organs. · DOI
- Dilliard, S. A. et al. The interplay of quaternary ammonium lipid structure and protein corona on lung-specific mRNA delivery by selective organ targeting (SORT) nanoparticles. J. Control. Rel. 361, 361–372 (2023). · DOI
- Ding, T. et al. Reciprocal interaction with neutrophils facilitates cutaneous accumulation of liposomes. ACS Nano 18, 18769–18784 (2024). · DOI
- Luo, Z. et al. Neutrophil hitchhiking for drug delivery to the bone marrow. Nat. Nanotechnol. 18, 647–656 (2023). · DOI · Paper page
- Kuang, J. et al. Nanoparticles hitchhike on monocytes for glioblastoma treatment after low-dose radiotherapy. ACS Nano 17, 13333–13347 (2023). · DOI
- Mu, Q. et al. Ligustrazine nanoparticle hitchhiking on neutrophils for enhanced therapy of cerebral ischemia–reperfusion injury. Adv. Sci. 10, 2301348 (2023). · DOI
- Kim, S. A. et al. Protein-based nanocages for vaccine development. J. Control. Rel. 353, 767–791 (2023). · DOI
- Lee, E. J., Lee, N. K. & Kim, I. S. Bioengineered protein-based nanocage for drug delivery. Adv. Drug Deliv. Rev. 106, 157–171 (2016). · DOI · Paper page
- Brauer, D. D. et al. Systematic engineering of a protein nanocage for high-yield, site-specific modification. J. Am. Chem. Soc. 141, 3875–3884 (2019). · DOI · Paper page
- Kwon, S. & Giessen, T. W. Engineered protein nanocages for concurrent RNA and protein packaging in vivo. ACS Synth. Biol. 11, 3504–3515 (2022). · DOI · Paper page
- Yoo, J. D. et al. Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy. Sci. Rep. 10, 19997 (2020). · DOI
- Zhang, J. et al. Cargo loading within ferritin nanocages in preparation for tumor-targeted delivery. Nat. Protoc. 16, 4878–4896 (2021). · DOI
- Ahn, B. et al. Four-fold channel-nicked human ferritin nanocages for active drug loading and pH-responsive drug release. Angew. Chem. Int. Ed. Engl. 57, 2909–2913 (2018). · DOI
- Divine, R. et al. Designed proteins assemble antibodies into modular nanocages. Science 372, eabd9994 (2021). · DOI · Paper page
- Yang, E. C. et al. Computational design of non-porous pH-responsive antibody nanoparticles. Nat. Struct. Mol. Biol. 31, 1404–1412 (2024). · DOI · Paper page
- Huddy, T. F. et al. Blueprinting extendable nanomaterials with standardized protein blocks. Nature 627, 898–904 (2024). This article reports the design of flexible protein building block system for the creation of new nanomedicines and nanomaterials. · DOI · Paper page
- Rennie, C. et al. In vivo behavior of systemically administered encapsulin protein nanocages and implications for their use in targeted drug delivery. Adv. Ther. 7, 2300360 (2024). · DOI
- Herrmann, I. K., Wood, M. J. A. & Fuhrmann, G. Extracellular vesicles as a next-generation drug delivery platform. Nat. Nanotechnol. 16, 748–759 (2021). · DOI · Paper page
- Cully, M. Exosome-based candidates move into the clinic. Nat. Rev. Drug Discov. 20, 6–7 (2021). · DOI · Paper page
- Wiklander, O. P. B. et al. Antibody-displaying extracellular vesicles for targeted cancer therapy. Nat. Biomed. Eng. 8, 1453–1468 (2024). · DOI
- Creeden, J. F. et al. Smart exosomes enhance PDAC targeted therapy. J. Control. Rel. 368, 413–429 (2024). · DOI
- Willms, E., Cabañas, C., Mäger, I., Wood, M. J. & Vader, P. Extracellular vesicle heterogeneity: subpopulations, isolation techniques, and diverse functions in cancer progression. Front. Immunol. 9, 738 (2018). · DOI · Paper page
- Gupta, D. et al. Quantification of extracellular vesicles in vitro and in vivo using sensitive bioluminescence imaging. J. Extracell. Vesicles 9, 1800222 (2020). · DOI · Paper page
- Whitehead, B. et al. Tumour exosomes display differential mechanical and complement activation properties dependent on malignant state: implications in endothelial leakiness. J. Extracell. Vesicles 4, 29685 (2015). · DOI · Paper page
- Xia, Y., Zhang, J., Liu, G. & Wolfram, J. Immunogenicity of extracellular vesicles. Adv. Mater. 36, 2403199 (2024). · DOI · Paper page
- Wu, J. P. et al. Reloadable multidrug capturing delivery system for targeted ischemic disease treatment. Sci. Transl. Med. 8, 365ra160 (2016). · DOI
- Chuang, K. H. et al. Endocytosis of PEGylated agents enhances cancer imaging and anticancer efficacy. Mol. Cancer Ther. 9, 1903–1912 (2010). · DOI
- Huang, W.-C. et al. Engineering chimeric receptors to investigate the size-and rigidity-dependent interaction of PEGylated nanoparticles with cells. ACS Nano 10, 648–662 (2016). · DOI
- Moles, E. et al. Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia. Sci. Transl. Med. 15, eabm1262 (2023). · DOI
- Kim, J. et al. Translational development of a tumor junction opening technology. Sci. Rep. 12, 7753 (2022). · doi:10.1038/s41598-022-11843-z
- Beyer, I. et al. Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs. Clin. Cancer Res. 18, 3340–3351 (2012). · DOI
- Chen, M. et al. A novel anti-tumor/anti-tumor-associated fibroblast/anti-mPEG tri-specific antibody to maximize the efficacy of mPEGylated nanomedicines against fibroblast-rich solid tumor. Biomater. Sci. 10, 202–215 (2022). · DOI
- Schiller, J. L., Marvin, A., McCallen, J. D. & Lai, S. K. Robust antigen-specific tuning of the nanoscale barrier properties of biogels using matrix-associating IgG and IgM antibodies. Acta Biomater. 89, 95–103 (2019). · DOI
- Schiller, J. L. et al. Antibody-mediated trapping in biological hydrogels is governed by sugar–sugar hydrogen bonds. Acta Biomater. 107, 91–101 (2020). · DOI
- Chithrani, B. D., Ghazani, A. A. & Chan, W. C. W. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 6, 662–668 (2006). · DOI · Paper page
- Kao, C. H. et al. One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles. Biomaterials 35, 9930–9940 (2014). · DOI
- Chen, H.-J. et al. Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG × CD20). Cancer Nanotechnol. 14, 78 (2023). · DOI
- Cheng, W.-J. et al. Active tumoral/tumor environmental dual-targeting by non-covalently arming with trispecific antibodies or dual-bispecific antibodies on docetaxel-loaded mPEGylated nanocarriers to enhance chemotherapeutic efficacy and Minimize systemic toxicity. Int. J. Nanomed. 16, 4017–4030 (2021). · DOI
- Meng, J.-L. et al. pH-responsive polyethylene glycol engagers for enhanced brain delivery of PEGylated nanomedicine to treat glioblastoma. ACS Nano 19, 307–321 (2025). This article reports PEG engagers designed to increase nanoparticle delivery across the blood–brain barrier. · DOI
- Ho, K.-W. et al. Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity. J. Nanobiotechnol. 19, 1–12 (2021). · DOI
- Beishenaliev, A. et al. Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: a review. J. Control. Rel. 359, 268–286 (2023). · DOI
200 of 222 shown
Cited by
El-khawaga, A. M., Youssef, O. I., El-dydamoni, O. A., Ragab, W. M., & Mohammed, R. A. E. (2026) · European Journal of Medical Research · doi:10.1186/s40001-025-03804-9 · Cited by 14
“These coatings further help in reducing immunogenic responses [59].”
Zhu, J., Bai, L., Wang, C., Liu, J., Chen, Y., Zhang, W., Weng, J., Wei, L., & Wei, Z. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103505
Self-citation
Metadata
- Authors
- Chen, Y., Su, Y.-C., & Roffler, S. R.
- ORCID
- Roffler, Steve R.
- Venue
- Nature Reviews Bioengineering
- Published
- 2025-06-10
- Volume
- 3
- Issue
- 9
- Pages
- 742-760
- ISSN
- 2731-6092
- Cited by
- 113
- References
- 21
- Language
- en
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Polyethylene glycol immunogenicity in nanomedicine. https://app.cochat.ai/papers/10.1038/s44222-025-00321-6
- The paper
- Chen, Y., Su, Y.-C., & Roffler, S. R. (2025). Polyethylene glycol immunogenicity in nanomedicine. Nature Reviews Bioengineering. https://doi.org/10.1038/s44222-025-00321-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.